Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters

Sorafenib in liver cancer

(2012) Hyun Young Woo et al.   EXPERT OPINION ON PHARMACOTHERAPY

Anthracene-Tethered Ruthenium(II) Arene Complexes as Tools To Visualize the Cellular Localization of Putative Organometallic Anticancer Compounds

(2012) Alexey A. Nazarov et al.   INORGANIC CHEMISTRY

Challenges and Opportunities in the Development of Organometallic Anticancer Drugs

(2012) Christian G. Hartinger et al.   ORGANOMETALLICS

A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity

(2012) Anna Astashkina et al.   PHARMACOLOGY & THERAPEUTICS

Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules

(2011) Muhammad Hanif et al.   CHEMICAL COMMUNICATIONS

Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics

(2011) Christian G. Hartinger et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Metal-based antitumour drugs in the post-genomic era: what comes next?

(2011) Gianni Sava et al.   DALTON TRANSACTIONS

Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion

(2011) Patrycja Nowak-Sliwinska et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity

(2011) Patrycja Nowak-Sliwinska et al.   JOURNAL OF MEDICINAL CHEMISTRY

Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation

(2011) Bin Wu et al.   NUCLEIC ACIDS RESEARCH

Osmium(ii)–versus ruthenium(ii)–arene carbohydrate-based anticancer compounds: similarities and differences

(2010) Muhammad Hanif et al.   DALTON TRANSACTIONS

Photoactivated Biological Activity of Transition-Metal Complexes

(2010) Ulrich Schatzschneider   EUROPEAN JOURNAL OF INORGANIC CHEMISTRY

Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

(2009) Jorg Hartmann et al.   CURRENT DRUG METABOLISM

Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model

(2009) Patrycja Nowak-Sliwinska et al.   MICROVASCULAR RESEARCH

KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

(2008) Christian G. Hartinger et al.   CHEMISTRY & BIODIVERSITY

In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands

(2008) Isabella Berger et al.   CHEMISTRY-A EUROPEAN JOURNAL

Osmium Carbonyl Clusters: A New Class of Apoptosis Inducing Agents

(2008) Kien Voon Kong et al.   ChemMedChem

Carbohydrate-Metal Complexes and their Potential as Anticancer Agents

(2008) Christian Hartinger et al.   CURRENT MEDICINAL CHEMISTRY

Use of carbon monoxide as a therapeutic agent: promises and challenges

(2008) Roberta Foresti et al.   INTENSIVE CARE MEDICINE

The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways

(2008) Soumya Chatterjee et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY